Larimar Therapeutics (LRMR) Times Interest Earned (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Times Interest Earned came in at -$2133.9 in Q4 2025, down 36.38% YoY from -$3354.4 in Q4 2024, and down 5021.54% on a QoQ basis from -$41.67 in Q3 2025.
Larimar Therapeutics (LRMR) Times Interest Earned (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Times Interest Earned data on file, last reported at -$2133.9 in Q4 2025.
- Quarterly Times Interest Earned fell 36.38% year-over-year to -$2133.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5749.9 (down 26.52% YoY) and the FY2025 annual result came in at -$115.0, down 21792.26% from the prior year.
- Times Interest Earned declined to -$2133.9 in Q4 2025, from -$41.67 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.07 in Q4 2021 to a low of -$2133.9 in Q4 2025.
- A 5-year average of -$189.92 and a median of -$2.49 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2021 — Times Interest Earned jumped 86.58% — and 2024, when it tumbled 1566207.23%.
- Tracing LRMR's Times Interest Earned over 5 years: stood at -$0.07 in 2021, then decreased by 8.91% to -$0.08 in 2022, then dropped by 25.2% to -$0.1 in 2023, then plunged by 1566207.23% to -$1564.6 in 2024, then slumped by 36.38% to -$2133.9 in 2025.
- The last three Times Interest Earned figures came in at -$2133.9 (Q4 2025), -$41.67 (Q3 2025), and -$23.39 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | -5.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.79 |
| Dec 31, 2025 | -2,133.93 |
| Sep 30, 2025 | -41.67 |
| Jun 30, 2025 | -23.39 |
| Mar 31, 2025 | -5.16 |
| Dec 31, 2024 | -1,564.65 |
| Sep 30, 2024 | -2.47 |
| Jun 30, 2024 | -2.51 |
| Mar 31, 2024 | -1.52 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | -1.42 |
| Jun 30, 2023 | -1.37 |
| Mar 31, 2023 | -3.71 |
| Dec 31, 2022 | -0.08 |
| Sep 30, 2022 | -3.63 |
| Jun 30, 2022 | -3.48 |
| Mar 31, 2022 | -1.04 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | -5.65 |
| Jun 30, 2021 | -1.34 |